Abstract
Three subhepatocellular compartments concur for fatty acids degradation including β-oxidation in endoplasmic reticulum and β-oxidation in both mitochondria and peroxisomes. Deficits affecting the peroxisomal physiology may be associated with multiple metabolic disturbances. Nowadays, a growing body of evidence underlines the key role of peroxisomal β-oxidation in the sensing of lipid metabolism through the production/degradation of some essential metabolites. Lessons from several mice models strengthen the link between fatty acid β-oxidation in peroxisomes and the nuclear hormone receptor Peroxisome Proliferator-Activated Receptor (PPAR)-α with an additional level of coregualtor complexity, which couples regulation of body energetic balance and hepatic caloric flux to functional peroxisome status. Here, we review key determinants of disrupted peroxisomal β-oxidation pathway, which in liver promotes hepatic steatosis and hepatocarcinogenesis.
Keywords: ACOX1, Coactivators, hepatic Steatosis, hepatocarcinogenesis, MED1, NASH, beta-oxidation, Peroxisome, Peroxisomes proliferation, PPARalpha
Current Drug Metabolism
Title:Hepatic Steatosis and Peroxisomal Fatty Acid Beta-oxidation
Volume: 13 Issue: 10
Author(s): Mustapha Cherkaoui-Malki, Sailesh Surapureddi, Hammam I. El Hajj, Joseph Vamecq and Pierre Andreoletti
Affiliation:
Keywords: ACOX1, Coactivators, hepatic Steatosis, hepatocarcinogenesis, MED1, NASH, beta-oxidation, Peroxisome, Peroxisomes proliferation, PPARalpha
Abstract: Three subhepatocellular compartments concur for fatty acids degradation including β-oxidation in endoplasmic reticulum and β-oxidation in both mitochondria and peroxisomes. Deficits affecting the peroxisomal physiology may be associated with multiple metabolic disturbances. Nowadays, a growing body of evidence underlines the key role of peroxisomal β-oxidation in the sensing of lipid metabolism through the production/degradation of some essential metabolites. Lessons from several mice models strengthen the link between fatty acid β-oxidation in peroxisomes and the nuclear hormone receptor Peroxisome Proliferator-Activated Receptor (PPAR)-α with an additional level of coregualtor complexity, which couples regulation of body energetic balance and hepatic caloric flux to functional peroxisome status. Here, we review key determinants of disrupted peroxisomal β-oxidation pathway, which in liver promotes hepatic steatosis and hepatocarcinogenesis.
Export Options
About this article
Cite this article as:
Cherkaoui-Malki Mustapha, Surapureddi Sailesh, I. El Hajj Hammam, Vamecq Joseph and Andreoletti Pierre, Hepatic Steatosis and Peroxisomal Fatty Acid Beta-oxidation, Current Drug Metabolism 2012; 13 (10) . https://dx.doi.org/10.2174/138920012803762765
DOI https://dx.doi.org/10.2174/138920012803762765 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Delivery for Cancer Therapy
Current Drug Delivery Natural Products of Dietary Origin as Lead Compounds in Virtual Screening and Drug Design
Current Pharmaceutical Biotechnology Statins and Cancer
Anti-Cancer Agents in Medicinal Chemistry The Application of Pre-clinical Animal Models to Optimise Nanoparticulate Drug Delivery for Hepatocellular Carcinoma
Pharmaceutical Nanotechnology Cancer Stem Cells – Are Surface Markers Alone Sufficient?
Current Stem Cell Research & Therapy β-lactam Structured, 4-(4-(Methylsulfonyl)phenyl)-1-pentyl-3-phenoxyazetidin-2-one: Selectively Targets Cancerous B Lymphocyte Mitochondria
Anti-Cancer Agents in Medicinal Chemistry Structure-Based Drug Design to Overcome Drug Resistance: Challenges and Opportunities
Current Pharmaceutical Design Toxicogenomics to Evaluate Endocrine Disrupting Effects of Environmental Chemicals Using the Zebrafish Model
Current Genomics New Approaches to Target Cancer Stem Cells: Current Scenario
Mini-Reviews in Medicinal Chemistry LRP/LR as an Alternative Promising Target in Therapy of Prion Diseases, Alzheimers Disease and Cancer
Infectious Disorders - Drug Targets Cullin-RING Ligases as Attractive Anti-cancer Targets
Current Pharmaceutical Design Key Epigenetic Events Involved in the Maintenance of Breast Cancer Stem Cells
Current Stem Cell Research & Therapy Annexins in the Central Nervous System: Are they Neuroprotective or Proapoptotic Agents?
Medicinal Chemistry Reviews - Online (Discontinued) New Hopes in Cancer Battle - A Review of New Molecules and Treatment Strategies
Medicinal Chemistry E2F1-Mediated Apoptosis as a Target of Cancer Therapy
Current Molecular Pharmacology Potential Anti-cancer Drugs Commonly Used for Other Indications
Current Cancer Drug Targets Theranostic Applications of Lutetium-177 in Radionuclide Therapy
Current Radiopharmaceuticals The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML)
Current Signal Transduction Therapy P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design